Pfizer and Ginkgo Bioworks Join Forces for $331M RNA Drug Development Deal
Pfizer and Ginkgo Bioworks have entered into an R&D deal to develop RNA drugs, focusing on three therapeutic programs. The deal includes potential milestone payments of up to $331 million, with an undisclosed upfront amount. This collaboration reflects the growing importance of therapeutics in Ginkgo's business.